U.S. and Chinese researchers appear to have unlocked a novel way to stop T cells from attacking the body in MS and other ...

Autoimmune diseases, such as multiple sclerosis (MS), inflammatory bowel disease (IBD), and rheumatoid arthritis (RA), affect ...

When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered ...

New research has identified the gene Egr-1 as a critical regulator of immune balance, offering hope for autoimmune disease therapies.

In healthy adults, a single low dose of IMP761 continues to be safe and appears to reduce the activity of T-cells, a clinical ...

An engineered protein turns off the kind of immune cells most likely to damage tissue as part of Type-1 diabetes, hepatitis, ...

The University of Cincinnati joins a Phase 1 clinical trial testing CAR-T cell therapy for MS, exploring this cancer ...

T cells are the immune system’s frontline fighters. When they detect danger, they rapidly multiply and transform into ...

But when you have MS, B cells recruit T cells into your brain. There, they cause inflammation. When your number of B cells goes down, your amount of T cells that cause inflammation goes down, too.

They also activate T cells that attack myelin. That contributes to MS symptoms. But B-cell therapy helps change how B cells behave. That can ease MS symptoms and slow the progression of the condition.

The cancer therapy known as CAR-T has revolutionized treatment of some blood cancers since it was introduced in 2017. The therapy uses genetically altered immune cells to home in on cancer cells ...

Multiple sclerosis (MS) is a Th1-mediated autoimmune disease characterised by relapses followed by clinically stable remissions. A new hypothesis suggests that regulatory immune cells may play an ...